JP2022550816A5 - - Google Patents
Info
- Publication number
- JP2022550816A5 JP2022550816A5 JP2022520223A JP2022520223A JP2022550816A5 JP 2022550816 A5 JP2022550816 A5 JP 2022550816A5 JP 2022520223 A JP2022520223 A JP 2022520223A JP 2022520223 A JP2022520223 A JP 2022520223A JP 2022550816 A5 JP2022550816 A5 JP 2022550816A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- item
- antibody according
- seq
- conjugated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025066906A JP2025108588A (ja) | 2019-10-04 | 2025-04-15 | 抗ｐｄ－ｌ１抗体および抗体－薬物コンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910988P | 2019-10-04 | 2019-10-04 | |
| US62/910,988 | 2019-10-04 | ||
| PCT/US2020/054037 WO2021067776A2 (en) | 2019-10-04 | 2020-10-02 | Anti-pd-l1 antibodies and antibody-drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025066906A Division JP2025108588A (ja) | 2019-10-04 | 2025-04-15 | 抗ｐｄ－ｌ１抗体および抗体－薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022550816A JP2022550816A (ja) | 2022-12-05 |
| JP2022550816A5 true JP2022550816A5 (https=) | 2023-08-07 |
| JP7668791B2 JP7668791B2 (ja) | 2025-04-25 |
Family
ID=72964849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520223A Active JP7668791B2 (ja) | 2019-10-04 | 2020-10-02 | 抗ｐｄ－ｌ１抗体および抗体－薬物コンジュゲート |
| JP2025066906A Pending JP2025108588A (ja) | 2019-10-04 | 2025-04-15 | 抗ｐｄ－ｌ１抗体および抗体－薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025066906A Pending JP2025108588A (ja) | 2019-10-04 | 2025-04-15 | 抗ｐｄ－ｌ１抗体および抗体－薬物コンジュゲート |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12421312B2 (https=) |
| EP (1) | EP4038101A2 (https=) |
| JP (2) | JP7668791B2 (https=) |
| KR (1) | KR20220075351A (https=) |
| CN (1) | CN115151564B (https=) |
| AR (1) | AR120147A1 (https=) |
| AU (1) | AU2020358859A1 (https=) |
| BR (1) | BR112022005114A2 (https=) |
| CA (1) | CA3155634A1 (https=) |
| IL (1) | IL291541A (https=) |
| MX (1) | MX2022003517A (https=) |
| TW (1) | TWI883057B (https=) |
| WO (1) | WO2021067776A2 (https=) |
| ZA (1) | ZA202204437B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020466A2 (pt) * | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| EP4331616A4 (en) * | 2021-05-13 | 2026-03-18 | Univ Tsinghua | ANTIBODY-DRUG CONJUGATE, RELATED PREPARATION PROCESS AND ASSOCIATED USE |
| JP2024519907A (ja) * | 2021-05-21 | 2024-05-21 | レメゲン シーオー．，エルティーディー． | 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用 |
| WO2023126821A1 (en) * | 2021-12-29 | 2023-07-06 | Curateq Biologics Private Limited | C1q binding assay |
| CN118401564A (zh) * | 2022-01-18 | 2024-07-26 | Fbd生物制品有限公司 | 靶向cd47/pd-l1的蛋白质复合物和其使用方法 |
| EP4523704A1 (en) * | 2022-05-12 | 2025-03-19 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Camptothecin derivative and ligand-drug conjugate |
| JP2025525904A (ja) * | 2022-08-03 | 2025-08-07 | シージェン インコーポレイテッド | 免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート |
| WO2024078449A1 (en) | 2022-10-09 | 2024-04-18 | LaNova Medicines Limited | Compounds, compositions and methods |
| CN121969397A (zh) * | 2023-04-05 | 2026-05-01 | 维硕公司 | 抗体偶联药物及其用途 |
| EP4710944A1 (en) | 2023-05-09 | 2026-03-18 | Shanghai Henlius Biotech, Inc. | Anti-pdl1 antibody-drug conjugate and use |
| EP4490201A4 (en) | 2023-05-31 | 2026-03-11 | Fbd Biologics Ltd | CD47/PD-L1 Targeted Protein Complex and Its Methods of Use |
| AU2024317606A1 (en) * | 2023-07-29 | 2026-02-26 | Chimagen Biosciences, Ltd | Modified type e multi-specific antibodies |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| PT627940E (pt) | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| DK0871490T3 (da) | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| NZ513144A (en) | 1999-02-05 | 2003-05-30 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| PT1907424E (pt) * | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| PT2099823E (pt) | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Agentes de ligação ao alvo variantes e suas utilizações |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| DK3270965T3 (da) | 2015-03-18 | 2020-06-08 | Seattle Genetics Inc | Cd48-antistoffer og konjugater deraf |
| EP3432924A1 (en) * | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| ES2883297T3 (es) * | 2016-03-29 | 2021-12-07 | Stcube Inc | Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos |
| US11135307B2 (en) * | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| KR20200005540A (ko) | 2017-04-14 | 2020-01-15 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| EP3743448A4 (en) | 2018-01-26 | 2021-11-03 | Orionis Biosciences, Inc. | XCR1 BINDING AGENTS AND USES THEREOF |
| BR112020020466A2 (pt) * | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
-
2020
- 2020-10-02 EP EP20793914.1A patent/EP4038101A2/en active Pending
- 2020-10-02 CA CA3155634A patent/CA3155634A1/en active Pending
- 2020-10-02 JP JP2022520223A patent/JP7668791B2/ja active Active
- 2020-10-02 BR BR112022005114A patent/BR112022005114A2/pt unknown
- 2020-10-02 AR ARP200102743A patent/AR120147A1/es unknown
- 2020-10-02 US US17/061,998 patent/US12421312B2/en active Active
- 2020-10-02 MX MX2022003517A patent/MX2022003517A/es unknown
- 2020-10-02 AU AU2020358859A patent/AU2020358859A1/en active Pending
- 2020-10-02 WO PCT/US2020/054037 patent/WO2021067776A2/en not_active Ceased
- 2020-10-02 KR KR1020227012974A patent/KR20220075351A/ko active Pending
- 2020-10-02 CN CN202080082113.4A patent/CN115151564B/zh active Active
- 2020-10-05 TW TW109134497A patent/TWI883057B/zh active
-
2022
- 2022-03-21 IL IL291541A patent/IL291541A/en unknown
- 2022-04-20 ZA ZA2022/04437A patent/ZA202204437B/en unknown
-
2025
- 2025-04-15 JP JP2025066906A patent/JP2025108588A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022550816A5 (https=) | ||
| CN110240655B (zh) | 抗her2抗体及其缀合物 | |
| AU2012235817B2 (en) | Antibody-drug conjugates | |
| US20230073692A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| JP2021102648A (ja) | 抗ｆｏｌｒ１免疫複合体投与計画 | |
| US12441795B2 (en) | Anti-ROR1 antibodies and preparation method and uses thereof | |
| US11000598B2 (en) | Anti-HER2 biparatopic antibody-drug conjugates and methods of use | |
| JP2022506072A5 (https=) | ||
| CN107406497A (zh) | 半胱氨酸连接的纳米抗体二聚体 | |
| JP2022547434A (ja) | 標的化デンドリマー複合体 | |
| JP7455188B2 (ja) | コンジュゲーションのためのポリペプチド複合体及びその応用 | |
| WO2023102875A1 (en) | Anti-cdh6 antibody drug conjugate | |
| TW202540197A (zh) | 以結合191p4d12蛋白質之抗體藥物結合物(adc)治療癌症 | |
| WO2018232164A1 (en) | Antibody drug conjugates that bind lgr5 | |
| JP2024515266A5 (https=) | ||
| JP2026505934A (ja) | Ｔｒｏｐ２結合剤およびそのコンジュゲート | |
| CN103417965B (zh) | 一种含有抗vegf抗体的药物组合物 | |
| JP2026512687A (ja) | ヒト化ｌ１ｃａｍ抗体－薬物複合体 | |
| TW201922796A (zh) | 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑 | |
| JP7594708B1 (ja) | ネクチン４を標的としエキサテカンペイロードを含む抗体薬物コンジュゲート（ａｄｃ） | |
| JP2024540536A5 (https=) | ||
| JP2025521609A (ja) | 抗体可変領域の変異体及びその使用 | |
| WO2026018064A1 (en) | Multispecific multi-drug antibody-drug conjugates | |
| CN121319203A (zh) | 双特异性抗体和免疫偶联物及其用途 | |
| CN120173126A (zh) | 一种融合蛋白、包括其的adc及其应用 |